Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105702 · ClinicalTrials.gov registry record · Phase 2
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01105702: Clinical Trial Phase 2 study, sponsored by NYU Langone Health.
NCT01105702 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01105702, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.
Primary Outcome
PFS defined as time from date of diagnosis to most recent follow up, disease progression, or death. Disease progress defined as either clinical deterioration or radiographic progressive disease on magnetic resonance imaging (MRI) per updated response assessment in neuro-oncology criteria (Wen, et al).
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
- RADIATION Radiation
- DRUG Lithium Carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-05 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Why NCT01105702 stopped before completion
NCT01105702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT01105702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01105702 about?
NCT01105702 is a clinical study titled "Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma". This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.
What is the current status of trial NCT01105702?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2010-05. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01105702?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG), Radiation (RADIATION), Lithium Carbonate (DRUG).
Who is sponsoring clinical trial NCT01105702?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01105702's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia